Open report — full analysis, no account required.
Sign up to generate reports and read filings that aren't on the open list.
Get notified when ROIV files again. Create a free account and we'll email you the moment its next filing is analyzed.
Get filing alertsRoivant reports Phase 3 thyroid eye disease data, launches new hair loss trial, holds $4.3B cash
Filed April 2, 2026 · Period ending April 2, 2026 · ~1 min read
Key Changes
-
high
Immunovant reported topline Phase 3 results for batoclimab in thyroid eye disease, a pivotal readout that will determine whether the drug can advance to regulatory approval. Specific efficacy outcomes were not disclosed in the 8-K.
Item 8.01 Press Release view on EDGAR → -
high
Roivant held approximately $4.3 billion in cash, cash equivalents, and marketable securities as of March 31, 2026 (preliminary, unaudited). This strong balance sheet supports ongoing clinical programs and business development.
Item 8.01 Cash Position view on EDGAR → -
medium
Priovant initiated a Phase 2b/3 trial of brepocitinib for lichen planopilaris, a scarring hair loss condition. This expands the drug's potential indications beyond existing programs.
Item 8.01 Press Release view on EDGAR → -
medium
Roivant repurchased 3.96 million shares for $109.7 million during Q4 2026, averaging roughly $27.72 per share. This reflects ongoing capital return to shareholders under the buyback program.
Item 8.01 Share Repurchases view on EDGAR →
Summary
Roivant Sciences disclosed two major clinical milestones alongside a robust financial position. The company's subsidiary Immunovant reported topline Phase 3 results for batoclimab in thyroid eye disease, though the 8-K did not specify whether the trial met its endpoints. Separately, Priovant launched a new Phase 2b/3 study of brepocitinib for lichen planopilaris, a scarring hair loss disorder, broadening the drug's potential market.
Financially, Roivant ended the quarter with approximately $4.3 billion in cash and marketable securities and repurchased nearly 4 million shares for $109.7 million during Q4. The strong cash position provides runway for its multi-asset pipeline. Retail investors should watch for the full batoclimab Phase 3 data presentation, which will reveal whether the drug demonstrated statistically significant efficacy and a favorable safety profile—critical factors for regulatory approval and commercial viability in thyroid eye disease.
Section-by-Section Diff
Event · Item 2.02 — Results of Operations and Financial Condition
Roivant disclosed preliminary Q4 2026 cash of ~$4.3B and repurchased ~4M shares for ~$109.7M during the quarter.
Added in current filing · verify on EDGAR →
preliminary unaudited consolidated cash, cash equivalents and marketable securities as of March 31, 2026 of approximately $4.3 billion
The company disclosed preliminary cash, cash equivalents, and marketable securities of approximately $4.3 billion as of March 31, 2026. This is unaudited and subject to change as the fiscal year 2026 audit is ongoing.
Event · Item 7.01 — Regulation FD Disclosure
Roivant announces new Phase 2b/3 trial for brepocitinib in lichen planopilaris and reports topline Phase 3 results for batoclimab in thyroid eye disease.
Added in current filing · verify on EDGAR →
the Company issued a press release announcing a new Phase 2b/3 clinical program at Priovant for brepocitinib in lichen planopilaris
Roivant's subsidiary Priovant is launching a new Phase 2b/3 clinical trial to evaluate brepocitinib as a treatment for lichen planopilaris, a scarring hair loss condition. This represents a new indication expansion for the drug candidate and could broaden the commercial opportunity if successful.
Added in current filing · verify on EDGAR →
The press release also reported the topline results from Immunovant’s two Phase 3 clinical studies evaluating batoclimab as an investigational treatment for adults with active, moderate-to-severe thyroid eye disease
Immunovant, another Roivant subsidiary, has completed two Phase 3 studies of batoclimab for thyroid eye disease and is reporting topline results. While the 8-K does not detail whether the results were positive or negative, Phase 3 topline data is typically a major value driver as it determines whether a drug can proceed to regulatory approval.
Event · Item 9.01 — Financial Statements and Exhibits
Roivant Sciences filed an 8-K attaching a press release dated April 2, 2026; no material event details disclosed in the filing body.
Added in current filing · verify on EDGAR →
Press Release, dated April 2, 2026.
The 8-K references an attached press release dated April 2, 2026, but the filing body provides no details about the content or subject matter of the release. Without access to Exhibit 99.1, the nature and materiality of the disclosed event cannot be determined from this filing.
Thanks — your feedback helps us improve report quality.
Figures/quotes linked to EDGAR · Narrative written by AI · Jun 3, 2026 · How we verify